CWF19L1 Gene Spinocerebellar Ataxia Type 17 Autosomal Recessive Genetic Test
Welcome to DNA Labs UAE, your trusted genetic testing laboratory in the UAE. Today, we will be discussing the CWF19L1 Gene Spinocerebellar Ataxia Type 17 Autosomal Recessive Genetic Test. This test is designed to identify mutations in the CWF19L1 gene associated with spinocerebellar ataxia type 17 (SCA17), a neurodegenerative disorder.
Test Details
The CWF19L1 gene is responsible for SCA17, an autosomal dominant disorder. This means that a mutation in one copy of the gene is enough to cause the disease. Our Next-Generation Sequencing (NGS) technology allows us to analyze the DNA and identify any disease-causing mutations present in the CWF19L1 gene.
Symptoms and Diagnosis
Individuals with SCA17 may experience symptoms such as unsteady gait, poor coordination, speech difficulties, and involuntary movements. To diagnose SCA17, a thorough clinical history of the patient is taken, and a genetic counseling session is conducted to draw a pedigree chart of affected family members. This helps in determining the likelihood of inheriting the disorder.
Test Components and Price
The CWF19L1 Gene Spinocerebellar Ataxia Type 17 Autosomal Recessive Genetic Test costs AED 4400.0. The test requires a blood sample, extracted DNA, or one drop of blood on an FTA card. The report will be delivered within 3 to 4 weeks.
Test Type and Department
The CWF19L1 Gene Spinocerebellar Ataxia Type 17 Autosomal Recessive Genetic Test falls under the category of Neurological Disorders. It is conducted by our experienced team of neurologists in the Genetics department.
Pre Test Information
Before undergoing the CWF19L1 Gene Spinocerebellar Ataxia Type 17 Autosomal Recessive Genetic Test, it is important to provide the clinical history of the patient. This includes any relevant information about symptoms and family history. Additionally, a genetic counseling session will be conducted to assess the family pedigree and determine the risk of inheriting the disorder.
Benefits of Genetic Testing
Genetic testing for SCA17 can provide several benefits. It helps in diagnosing individuals with the condition, understanding the disease progression and prognosis, and assisting in family planning and genetic counseling. It is crucial to consult with a healthcare professional or genetic counselor to fully comprehend the implications, risks, and benefits associated with genetic testing.
At DNA Labs UAE, we are committed to providing accurate and reliable genetic testing services. Our state-of-the-art NGS technology and experienced team ensure the highest quality results. Contact us today to schedule your CWF19L1 Gene Spinocerebellar Ataxia Type 17 Autosomal Recessive Genetic Test.
| Test Name | CWF19L1 Gene Spinocerebellar ataxia type 17 autosomal recessive Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for CWF19L1 Gene Spinocerebellar ataxia type 17, autosomal recessive NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with CWF19L1 Gene Spinocerebellar ataxia type 17, autosomal recessive |
| Test Details |
The CWF19L1 gene is associated with a neurodegenerative disorder called spinocerebellar ataxia type 17 (SCA17). SCA17 is an autosomal dominant disorder, meaning that a mutation in one copy of the CWF19L1 gene is sufficient to cause the disease. NGS (Next-Generation Sequencing) genetic testing is a technique used to sequence the DNA of an individual and identify any variations or mutations in specific genes. In the case of SCA17, NGS genetic testing can be used to analyze the CWF19L1 gene and determine if there are any disease-causing mutations present. Autosomal recessive inheritance means that both copies of a gene must be mutated in order for a person to develop the disorder. However, SCA17 is an autosomal dominant disorder, so the term “autosomal recessive” may be a mistake in your question. Genetic testing for SCA17 can help diagnose individuals with the condition, provide information about disease progression and prognosis, and assist in family planning and genetic counseling. It is important to consult with a healthcare professional or genetic counselor to understand the implications of genetic testing and the potential risks and benefits associated with it. |
